Clinical Trial Update: Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus and mycophenolate mofetil for GVHD prophylaxis in myeloablative matched related donor hematopoietic cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Diseases
• Leukemia
• Lymphoma Non-hodgkin

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Stanford University | Conditions: Leukemia, Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED